Evaluation of Etest method for determining voriconazole and amphotericin B MICs for 162 clinical isolates of Cryptococcus neoformans

Journal of Clinical Microbiology

Volumn 41, Issue 1, 2003, Pages 97-99

  Maxwell, M J ^a   Messer, S A ^a   Hollis, R J ^a   Diekema, D J ^a   Pfaller, Michael A ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

AGAR; AMPHOTERICIN B; FLUCONAZOLE; GLUCOSE; VORICONAZOLE;

ANTIBIOTIC SENSITIVITY; ARTICLE; CLINICAL LABORATORY; CRYPTOCOCCUS NEOFORMANS; CULTURE MEDIUM; DEVICE; DILUTION; FUNGUS CULTURE; FUNGUS ISOLATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; STANDARD;

CRYPTOCOCCUS NEOFORMANS; FILOBASIDIELLA NEOFORMANS; FUNGI;

EID: 0037231946     PISSN: 00951137     EISSN: None     Source Type: Journal    
DOI: 10.1128/JCM.41.1.97-99.2003     Document Type: Article

References (24)

1. Aller, A. I., E. Martin-Mazuelos, M. J. Gutierrez, S. Bernal, M. Chavez, and F. J. Recio. 2000. Comparison of the Etest and microdilution method for antifungal susceptibility testing of Cryptococcus neoformans to four antifungal agents. J. Antimicrob. Chemother. 46:997-1000.
2. Barry, A. L., M. A. Pfaller, S. D. Brown, A. Espinel-Ingroff, M. A. Ghannoum, C. Knapp, R. P. Rennie, J. H. Rex, and M. G. Rinaldi. 2000. Quality control limits for broth microdilution susceptibility tests of ten antifungal agents. J. Clin. Microbiol. 38:3457-3459.
3. Brandt, M. E., M. A. Pfaller, R. A. Hajjeh, R. J. Hamill, P. G. Pappas, A. L. Reingold, D. Rimland, D. W. Warnock, and The Cryptococcal Disease Active Surveillance Group. 2001. Trends in antifungal drug susceptibility of Cryptococcus neoformans isolates in the United States: 1992 to 1994 and 1996 to 1998. Antimicrob. Agents Chemother. 45:3065-3069.
4. Chen, S. C. A., M. L. O'Donnell, S. Gordon, and G. L. Gilbert. 1996. Antifungal susceptibility testing using the Etest: comparison with the broth macrodilution technique. J. Antimicrob. Chemother. 37:265-273.
5. Colombo, A. L., F. Barcheisi, D. A. McGough, and M. G. Rinaldi. 1995. Comparison of Etest and National Committee for Clinical Laboratory Standards broth macrodilution method for azole antifungal susceptibility testing. J. Clin. Microbiol. 33:535-540.
6. Espinel-Ingroff, A., M. Pfaller, M. E. Erwin, and R. N. Jones. 1996. Interlaboratory evaluation of Etest method for testing antifungal susceptibilities of pathogenic yeasts to five antifungal agents by using Casitone agar and solidified RPMI 1640 medium with 2% glucose. J. Clin. Microbiol. 34:848-852.
7. Espinel-Ingroff, A., K. Boyle, and D. J. Sheehan. 2001. In vitro antifungal activities of voriconazole and reference agents as determined by NCCLS methods: review of the literature. Mycopathologia 150:101-115.
8. Lozano-Chiu, M., V. L. Paetznick, M. A. Ghannoum, and J. H. Rex. 1998. Detection of resistance to amphotericin B among Cryptococcus neofonnans clinical isolates: performance of three different media assessed by using E-Test and National Committee for Clinical Laboratory Standards M27-A methodologies. J. Clin. Microbiol. 36:2817-2822.
9. Marco, F., M. A. Pfaller, S. Messer, and R. N. Jones. 1998. In vitro activities of voriconazole (UK-109,496) and four other antifungal agents against 394 clinical isolates of Candida spp. Antimicrob. Agents Chemother. 42:161-163.
10. National Committee for Clinical Laboratory Standards. 1997. Reference method for broth dilution antifungal susceptibility testing of yeast. Approved standard M27-A. National Committee for Clinical Laboratory Standards, Wayne, Pa.
11. Petrou, M. A., and D. C. Shanson. 2000. Susceptibility of Cryptococcus neoformans by the NCCLS microdilution and Etest methods using five defined media. J. Antimicrob. Chemother. 46:815-818.
12. Pfaller, M. A., S. A. Messer, and A. Bolmström. 1998. Evaluation of Etest for determining in vitro susceptibility of yeast isolates to amphotericin B. Diagn. Microbiol. Infect. Dis. 32:223-227.
13. Pfaller, M. A., S. A. Messer, A. Karlsson, and A. Bolmström. 1998. Evaluation of the Etest method for determining fluconazole susceptibilities of 402 clinical yeast isolates by using three different agar media. J. Clin. Microbiol. 36:2586-2589.
14. Pfaller, M. A., J. Zhang, S. A. Messer, M. E. Brandt, R. A. Hajjeh, C. J. Jessup, M. Tumerland, E. K. Mbidde, and M. A. Ghannoum. 1999. In vitro activities of voriconazole, fluconazole, and itraconazole against 566 clinical isolates of Cryptococcus neoformans from the United States and Africa. Antimicrob. Agents Chemother. 43:169-171.
15. Pfaller, M. A., S. A. Messer, A. Houston, K. Mills, A. Bolmström, and R. N. Jones. 2000. Evaluation of the Etest method for determining voriconazole susceptibilities of 312 clinical isolates of Candida species by using three different agar media. J. Clin. Microbiol. 38:3715-3717.
16. Pfaller, M. A., S. A. Messer, K. Mills, A. Bolmström, and R. N. Jones. 2001. Evaluation of Etest method for determining caspofungin (MK-0991) susceptibilities of 726 isolates of Candida species. J. Clin. Microbiol. 49:4387-4389.
17. Pfaller, M. A., S. A. Messer, K. Mills, A. Bolmström, and R. N. Jones. 2001. Evaluation of Etest method for determining posaconazole MICs for 314 clinical isolates of Candida species. J. Clin. Microbiol. 39:3952-3954.
18. Pfaller, M. A., D. J. Diekema, R. N. Jones, H. S. Sader, A. C. Fluit, R. J. Hollis, S. A. Messer, and the SENTRY Participant Group. 2001. International surveillance of bloodstream infections due to Candida species: frequency of occurrence and in vitro susceptibilities to fluconazole, ravuconazole, and voriconazole of isolates collected from 1997 through 1999 in the SENTRY Antimicrobial Surveillance Program. J. Clin. Microbiol. 39:3254-3259.
19. Radford, S. A., E. M. Johnson, and D. W. Warnock. 1997. In vitro studies of activity of voriconazole (UK-109,496), a new triazole antifungal agent against emerging and less-common mold pathogens. Antimicrob. Agents Chemother. 41:841-843.
20. Sabo, J. A., and S. M. Abdel-Rahman. 2000. Voriconazole: a new triazole antifungal. Ann. Pharmacother. 34:1032-1043.
21. Simor, A. E., G. Goswell, L. Louie, M. Lee, and M. Louie. 1997. Antifungal susceptibility testing of yeast isolates from blood cultures by microbroth dilution and the Etest. Eur. J. Clin. Microbiol. Infect. Dis. 16:693-697.
22. Verweij, P. E., B. E. de Pauw, and J. F. Meis. 1999. Voriconazole. Curr. Opin. Anti-Infect. Investig. Drugs 1:361-372.
23. Warnock, D. W., E. M. Johnson, and T. F. Rogers. 1998. Multi-centre evaluation of the Etest method for antifungal drug susceptibility testing of Candida spp. and Cryptococcus neoformans. J. Antimicrob. Chemother. 42:321-331.
24. Yamazumi, T., M. A. Pfaller, S. A. Messer, A. Houston, R. J. Hollis, and R. N. Jones. 2000. In vitro activities of ravuconazole (BMS-207147) against 541 clinical isolates of Cryptococcus neoformans. Antimicrob. Agents Chemother. 44:2883-2886.